Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study)

PURPOSE: This study investigated the efficacy and safety of cetuximab-based treatment in patients with chemotherapy-resistant refractory mCRC with KRAS G13D mutation. PATIENTS AND METHODS: An assessment of the efficacy and safety of cetuximab-based treatment was performed in an observation-enriched...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Cancer Chemother Pharmacol
Hoofdauteurs: Nakamura, Masato, Aoyama, Toru, Ishibashi, Keiichiro, Tsuji, Akihito, Takinishi, Yasutaka, Shindo, Yoshiaki, Sakamoto, Junichi, Oba, Koji, Mishima, Hideyuki
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Springer Berlin Heidelberg 2016
Onderwerpen:
Original Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5225170/
https://ncbi.nlm.nih.gov/pubmed/27878354
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-016-3203-7
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items